Summary
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2016’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ankylosing Spondylitis (Bekhterev's Disease) therapeutics and enlists all their major and minor projects
- The report assesses Ankylosing Spondylitis (Bekhterev's Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alteogen Inc.
Amgen Inc.
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Brickell Biotech, Inc.
Celgene Corporation
Celltrion, Inc.
Coherus BioSciences, Inc.
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Lupin Limited
Mabion SA
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Protalix BioTherapeutics, Inc.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Swedish Orphan Biovitrum AB
Therapeutic Proteins International, LLC
Vitae Pharmaceuticals, Inc.
Xbrane Biopharma AB
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ankylosing Spondylitis (Bekhterev's Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 9
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 10
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 17
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 20
Alteogen Inc. 20
Amgen Inc. 21
BIOCAD 22
Biocon Limited 23
Bionovis SA 24
Boehringer Ingelheim GmbH 25
Brickell Biotech, Inc. 26
Celgene Corporation 27
Celltrion, Inc. 28
Coherus BioSciences, Inc. 29
Epirus Biopharmaceuticals, Inc. 30
Genor BioPharma Co., Ltd. 31
Innovent Biologics, Inc. 32
Johnson & Johnson 33
Lupin Limited 34
Mabion SA 35
Momenta Pharmaceuticals, Inc. 36
Mycenax Biotech Inc. 37
Novartis AG 38
Oncobiologics, Inc. 39
Panacea Biotec Limited 40
Protalix BioTherapeutics, Inc. 41
Sandoz International GmbH 42
Shanghai Pharmaceutical Co., Ltd. 43
Swedish Orphan Biovitrum AB 44
Therapeutic Proteins International, LLC 45
Vitae Pharmaceuticals, Inc. 46
Xbrane Biopharma AB 47
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
adalimumab biosimilar - Drug Profile 57
adalimumab biosimilar - Drug Profile 58
adalimumab biosimilar - Drug Profile 60
adalimumab biosimilar - Drug Profile 61
adalimumab biosimilar - Drug Profile 62
adalimumab biosimilar - Drug Profile 63
adalimumab biosimilar - Drug Profile 64
adalimumab biosimilar - Drug Profile 65
adalimumab biosimilar - Drug Profile 66
adalimumab biosimilar - Drug Profile 67
adalimumab biosimilar - Drug Profile 68
adalimumab biosimilar - Drug Profile 70
adalimumab biosimilar - Drug Profile 71
adalimumab biosimilar - Drug Profile 72
adalimumab biosimilar - Drug Profile 73
adalimumab biosimilar - Drug Profile 74
anakinra (recombinant) - Drug Profile 75
apremilast - Drug Profile 77
BBI-6000 - Drug Profile 80
certolizumab pegol biosimilar - Drug Profile 82
COVA-322 - Drug Profile 83
DNX-114 - Drug Profile 84
etanercept biosimilar - Drug Profile 85
etanercept biosimilar - Drug Profile 86
etanercept biosimilar - Drug Profile 87
etanercept biosimilar - Drug Profile 88
etanercept biosimilar - Drug Profile 89
etanercept biosimilar - Drug Profile 90
etanercept biosimilar - Drug Profile 91
etanercept biosimilar - Drug Profile 93
etanercept biosimilar - Drug Profile 94
etanercept biosimilar - Drug Profile 95
golimumab - Drug Profile 96
golimumab biosimilar - Drug Profile 100
golimumab biosimilar - Drug Profile 101
golimumab biosimilar - Drug Profile 102
infliximab biosimilar - Drug Profile 103
infliximab biosimilar - Drug Profile 104
infliximab biosimilar - Drug Profile 105
infliximab biosimilar - Drug Profile 107
infliximab biosimilar - Drug Profile 108
infliximab biosimilar - Drug Profile 109
infliximab biosimilar - Drug Profile 110
infliximab biosimilar - Drug Profile 111
INV-17 - Drug Profile 112
risankizumab - Drug Profile 113
secukinumab - Drug Profile 115
thalidomide - Drug Profile 121
VTP-43742 - Drug Profile 122
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 123
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 161
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 163
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 164
Featured News & Press Releases 164
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 173
Disclaimer 174
List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2016 13
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc., H1 2016 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2016 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H1 2016 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2016 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H1 2016 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Brickell Biotech, Inc., H1 2016 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2016 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2016 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences, Inc., H1 2016 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 35
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2016 36
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H1 2016 37
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H1 2016 38
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabion SA, H1 2016 39
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 40
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc., H1 2016 41
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H1 2016 42
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H1 2016 43
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2016 44
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 45
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H1 2016 46
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 47
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Swedish Orphan Biovitrum AB, H1 2016 48
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2016 49
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 50
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H1 2016 51
Assessment by Monotherapy Products, H1 2016 52
Number of Products by Stage and Target, H1 2016 54
Number of Products by Stage and Mechanism of Action, H1 2016 56
Number of Products by Stage and Route of Administration, H1 2016 58
Number of Products by Stage and Molecule Type, H1 2016 60
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2016 127
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2016 165
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H1 2016 166
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2016 167
List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 52
Number of Products by Targets, H1 2016 53
Number of Products by Stage and Targets, H1 2016 53
Number of Products by Mechanism of Actions, H1 2016 55
Number of Products by Stage and Mechanism of Actions, H1 2016 55
Number of Products by Routes of Administration, H1 2016 57
Number of Products by Stage and Routes of Administration, H1 2016 57
Number of Products by Molecule Types, H1 2016 59
Number of Products by Stage and Molecule Types, H1 2016 59
